Should general practitioners use dithranol?

Donaldson, Judith; Cunliffe, W.J.
June 1983
British Medical Journal (Clinical Research Edition);6/18/1983, Vol. 286 Issue 6382, p1939
Academic Journal
Examines the treatment of dithranol for patients with psoriasis. Improvement on the cosmetic acceptability of some dithranol preparations; Effectiveness of dithranol application to the skin for one hour; Details on the conventional regimen of dithranol treatment.


Related Articles

  • Psychosocial component is critical to comprehensive psoriasis approach. Nataloni, Rochelle // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS25 

    Focuses on the role of psychosocial component to comprehensive psoriasis approach. Assessment of the extent of the psoriasis; Evaluation of the patient's psychosocial needs; Relationship between the extent of tumor lymphangiogenesis and both lymph mode.

  • Tazarotene/corticosteroid proven superior Tx for plaque psoriasis. Guttman, Cheryl // Dermatology Times;Jun2001, Vol. 22 Issue 6, p13 

    Reports on the efficacy of switching treatment for plaque psoriasis from calcipotrine plus a corticosteroid to tazarotene 0.1 percent gel. Improvement of disease status; High level of patient satisfaction; Patient requirements; Drug tolerance.

  • Treatment Options for Patients with Psoriasis. Kilic, Arzu; Gul, Ulker // European Dermatology;2010, Vol. 5, p16 

    Psoriasis is a chronic inflammatory disease that is the result of complex interactions between genetic, enviromental and immunological factors. It is now accepted as a systemic disorder accompanied by co-morbidities, rather than simply a cutaneous disease. Treatment of a patient with psoriasis...

  • Topical calcipotriol/betamethasone dipropionate achieves quicker response against psoriasis compared with biological therapies77,77.  // Formulary;Oct2006, Vol. 41 Issue 10, p533 

    The article reports on the effectiveness of topical calcipotriol with betamethasone diproprionate in treating psoriasis compared with biological therapy. The ointment's efficacy is discovered when measured by the Psoriasis Area and Severity Index. After 4 weeks of treatment with the ointment,...

  • Some Observations on Reporting Quality of Life in Treatment of Psoriasis in Outpatient Clinics. Lindberg, Magnus; Berg, Mats // Acta Dermato-Venereologica;2013, Vol. 93 Issue 2, p210 

    The article discusses a study on whether the Dermatology Life Quality Index (DLQI) and/or the visual analogue scale (VAS) could be recommended for use in everyday practice for treatment follow-ups in psoriasis in Swedish outpatient clinics. The DLQI is described as a quality of life instrument...

  • PSUNRISE progress. Krader, Cheryl Guttman // Dermatology Times;Aug2010, Vol. 31 Issue 8, p28 

    The article reports on a research investigation regarding the use of infliximab in patients with psoriasis in the U.S. Further evidence depicts that the value of the TNF-alpha blocker infliximab has been used as a therapeutic option. The Prospective Study Using Remicade in Psoriasis Patients...

  • Management of Patients with Psoriasis in Japan.  // Advances in Psoriasis & Inflammatory Skin Diseases;2011, Vol. 2 Issue 4, p126 

    The article describe the characteristics of psoriasis in Japanese patients and presents an overview of the management of the disease in this population. The data of the Japanese Society for Psoriasis Research indicate that most of the psoriasis suffered by Japanese patients is psoriasis...

  • Efficacy, Safety, and Out-of-pocket Costs are the Most Important Factors to Patients in Choosing a Psoriasis Therapy. SECREST, AARON M.; MATINRAZM, ALI; FERRIS, LAURA K. // Journal of Clinical & Aesthetic Dermatology;Dec2014, Vol. 7 Issue 12, p30 

    Objective: To determine which factors (i.e., cost, efficacy, safety, and method of delivery) influence choice of psoriasis treatment by patients and how patients obtain information regarding treatment options. Design: Anonymous survey. Setting: Specialty Psoriasis Clinic at an academic...

  • Living with Psoriasis. Paranzino, Michael // FDA Consumer;Sep2004, Vol. 38 Issue 5, p40 

    Reflects on life as a psoriasis patient. Characterization of the disease; Physical and emotional effects of psoriasis; Increase in the efforts of the U.S. government to develop psoriasis treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics